| Literature DB >> 30542649 |
Alexander Pöthig1, Sara Ahmed2, Hanne Cecilie Winther-Larsen2, Shengyang Guan1, Philipp J Altmann1, Jürgen Kudermann1, Adriana Magalhães Santos Andresen2, Tor Gjøen2, Ove Alexander Høgmoen Åstrand3.
Abstract
The biological activity of four pillarplex compounds featuring different metals and anions was investigated. The toxicity of the compounds against four bacterial strains [Bacillus subtilis (ATCC6633), Staphylococcus aureus (ATCC6538), Escherichia coli (UVI isolate), Pseudomonas aeruginosa], one fungus (Candida albicans), and a human cell line (HepG2) was determined. Additionally, a UV-Vis titration study of the pillarplexes was carried out to check for stability depending on pH- and chloride concentration changes and evaluate the applicability in physiological media. All compounds are bioactive: the silver compounds showed higher activity against bacteria and fungi, and the corresponding gold pillarplexes were less toxic against human cells.Entities:
Keywords: NHC; antimicrobial; cytotoxicity; gold; organometallic; silver; stability; supramolecular
Year: 2018 PMID: 30542649 PMCID: PMC6277803 DOI: 10.3389/fchem.2018.00584
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Figure 1(Left) Overview of related known biomedical relevant compound classes. (Right) NHC based organometallocavitands including precursor investigated in this study.
Results from the disc diffusion assay for compounds 1–8 (10 mM) as well as reference substrates (30 mg/ml for tetracycline and gentamycine sulfate, and 10 mM for miconazole nitrate).
| 1 | H6LMe(PF6)4 ( | 0 ± 0 | 0 ± 0 | 0 ± 0 | 6.4 ± 0.4 | 0 ± 0 |
| 2 | H6LMe(OTf)4 ( | 0 ± 0 | 0 ± 0 | 6.7 ± 0.4 | 6.8 ± 0.3 | 0 ± 0 |
| 3 | [Ag8(LMe)2] (PF6)4 ( | 8.6 ± 0.2 | 8.0 ± 0.7 | 9.1 ± 1.7 | 8.3 ± 0.3 | 10.1 ± 0.4 |
| 4 | [Ag8(LMe)2] (OAc)4 ( | 8.0 ± 0 | 8.2 ± 0.6 | 9.2 ± 2.1 | 7.8 ± 0.4 | 9.2 ± 0.9 |
| 5 | [Au8(LMe)2] (PF6)4 ( | 7.4 ± 0.4 | 0 ± 0 | 7.4 ± 0.6 | 0 ± 0 | 0 ± 0 |
| 6 | [Au8(LMe)2] (OAc)4 ( | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| 7 | AgNO3 | 7.8 ± 0.3 | 7.4 ± 0.6 | 8.9 ± 1.8 | 6.3 ± 0.5 | 9.6 ± 0.4 |
| 8 | AuCl3 | 8.6 ± 0.4 | 8 ± 0 | 8.9 ± 1.7 | 7.3 ± 0.4 | 0 ± 0 |
| 9 | DMSO | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| 10 | Miconazole nitrate | – | – | – | – | 17.1 ± 0.8 |
| 11 | Tetracycline | – | – | – | 28.9 ± 0.5 | – |
| 12 | Gentamycin sulfate | 23.7 ± 1.6 | 23.0 ± 0.7 | 23.7 ± 1.6 | – | – |
negative control,
positive control.
IC50-values for compounds 1–6 as well as reference salts against human liver cells (HepG2).
| IC50 ± SE (μM) | 467.5 ± 1.4 | 402.2 ± 1.1 | 88 | 56 | 72.4 ± 1.0 | 29.9 ± 1.0 | 127 | 274 |
Precipitation occurred, therefore IC.
Figure 2(A) Normalized UV-Vis absorption spectra of the ligand precursor (gray) and pillarplexes 4 (blue), and 6 (orange). (B) Titration experiment of compounds 4 (blue) and 6 (orange) against sodium chloride, showing the decay of the normalized signal at the individual absorption maximum (226 nm for 4, 245 nm for 6) including statistical uncertainties.
Figure 3(A) Stability test at different pH-values showing decay of normalized absorption of silver pillarplex 4 (blue) at 226 nm over time. (B) Stability test at different pH-values showing decay of normalized absorption of gold pillarplex 6 (orange) at 245 nm over time.